Search
Eligo Bioscience

Eligo Bioscience

Eligobiotics provides a new approach to explore, understand, and control bacterial ecosystems both in human and animals.

Paris Ile-de-France France
Industry IconBiotechnology
Email Icon11-50 employés
Founded on 2014-01-01
Social Icon
Social Icon
Social Icon

Overview

Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.

Sources

Growth Insight

Eligo Bioscience may be growing as it has recently raised significant capital, specifically a $30 million investment, which indicates a strong financial influx supporting its operations and research. This funding is being directed towards advancing new treatments, including an innovative acne treatment, demonstrating the company's active product development efforts. Furthermore, the successful closure of a Series B funding round for its microbiome gene-editing technology suggests confidence from investors in Eligo Bioscience's potential and strategic direction.

Funding

Total Round:9
Funding Total:
Financing Time:2023-12-05
Financing Stage:series_b
Financing Amount:69,706,775 USD

Core Team

  • Luciano Marraffini

    Co-founder

  • Timothy K. Lu

    Co-Founder | 2014-01-01

  • David Bikard

    CSO & Co-founder | 2014-01-01

  • Xavier Duportet

    Co-founder/CEO | 2014-06-01

  • Antoine Decrulle

    Research Scientist

Events

No Events Available

Tech Stack

  • Domain Not Resolving

    hosting
  • Euro

    payment
  • Cloudflare Hosting

    hosting
  • Cloudflare Blocked

    cdn

FAQ of Eligo Bioscience

Coming soon

Similar Companies